Changing the course of pancreatic cancer - Focus on recent translational advances

Cancer Treatment Reviews

Volumn 44, Issue , 2016, Pages 17-25

  Javle, Milind ^a   Golan, Talia ^b   Maitra, Anirban ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Carcinoma; Pancreatic ductal; Translational medical research

Indexed keywords

ALGENPANTUCEL L; CANCER VACCINE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLOPHOSPHAMIDE; GEMCITABINE; INTERLEUKIN 10; LONAFARNIB; PACLITAXEL; PATIDEGIB; PEGYLATED INTERLEUKIN 10; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB; TRAMETINIB; TRANSCRIPTION FACTOR YAP1; UNCLASSIFIED DRUG; KRAS PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN P21;

ADOPTIVE T CELL TRANSFER; ADOPTIVE TRANSFER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE COURSE; DNA REPAIR; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; EVIDENCE BASED MEDICINE; EXTRACELLULAR MATRIX; GENE TARGETING; HUMAN; IMMUNOLOGICAL TOLERANCE; LETHALITY; MALIGNANT TRANSFORMATION; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATIC STELLATE CELL; PANCREATIC STROMA; PERSONALIZED MEDICINE; PROGRESSION FREE SURVIVAL; PROTEIN DEPLETION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; STROMA; SURVIVAL RATE; SURVIVAL TIME; SYNTHETIC LETHALITY; TRANSGENIC MOUSE; TRANSLATIONAL RESEARCH; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; ADOPTIVE IMMUNOTHERAPY; CARCINOMA, PANCREATIC DUCTAL; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PANCREATIC NEOPLASMS; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE;

CANCER VACCINES; CARCINOMA, PANCREATIC DUCTAL; DNA REPAIR; GENES, BRCA1; GENES, BRCA2; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS); T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MICROENVIRONMENT;

EID: 84964219080     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.01.004     Document Type: Review

References (89)

1. Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014, 74(11):2913-2921.
2. A plan of attack for deadly cancers. Cancer Discovery 2014; 4(9): 980.
3. Erkan M. Understanding the stroma of pancreatic cancer: co-evolution of the microenvironment with epithelial carcinogenesis. J Pathol 2013, 231(1):4-7.
4. Waghray M., Yalamanchili M., di Magliano M.P., Simeone D.M. Deciphering the role of stroma in pancreatic cancer. Curr Opin Gastroenterol 2013, 29(5):537-543.
5. Krantz S.B., Shields M.A., Dangi-Garimella S., et al. MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-beta signaling. Mol Cancer Res MCR 2011, 9(10):1294-1304.
6. Kikuta K., Masamune A., Watanabe T., et al. Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem Biophys Res Commun 2010, 403(3-4):380-384.
7. Xu Z., Pothula S.P., Wilson J.S., Apte M.V. Pancreatic cancer and its stroma: a conspiracy theory. World J Gastroenterol WJG 2014, 20(32):11216-11229.
8. Neuzillet C., Tijeras-Raballand A., Cros J., Faivre S., Hammel P., Raymond E. Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer Metastasis Rev 2013, 32(3-4):585-602.
9. Von Hoff D.D., Ervin T., Arena F.P., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013, 369(18):1691-1703.
10. Hidalgo M., Plaza C., Musteanu M., et al. SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT trial. Clin Cancer Res Off J Am Assoc Cancer Res 2015, 21(21):4811-4818.
11. Provenzano P.P., Cuevas C., Chang A.E., Goel V.K., Von Hoff D.D., Hingorani S.R. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21(3):418-429.
12. Hingorani SR, Harris WP, Hendifar AE, et al., High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized phase II study, ASCO Meeting Abstracts 33(suppl. 15), 2015, p. 4006.
13. Soucek L., Buggy J.J., Kortlever R., et al. Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma. Neoplasia 2011, 13(11):1093-1100.
14. Olive K.P., Jacobetz M.A., Davidson C.J., et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324(5933):1457-1461.
15. Rhim A.D., Oberstein P.E., Thomas D.H., et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 2014, 25(6):735-747.
16. Ozdemir B.C., Pentcheva-Hoang T., Carstens J.L., et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014, 25(6):719-734.
17. Pylayeva-Gupta Y., Grabocka E., Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011, 11(11):761-774.
18. Jones S., Zhang X., Parsons D.W., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321(5897):1801-1806.
19. Biankin A.V., Waddell N., Kassahn K.S., et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012, 491(7424):399-405.
20. Lennerz J.K., Stenzinger A. Allelic ratio of KRAS mutations in pancreatic cancer. Oncologist 2015, 20(4):e8-9.
21. Witkiewicz A.K., McMillan E.A., Balaji U., et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 2015, 6:6744.
22. di Magliano M.P., Logsdon C.D. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 2013, 144(6):1220-1229.
23. Collisson E.A., Sadanandam A., Olson P., et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011, 17(4):500-503.
24. McCormick F. KRAS as a therapeutic target. Clin Cancer Res Off J Am Assoc Cancer Res 2015, 21(8):1797-1801.
25. Maurer T., Garrenton L.S., Oh A., et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci USA 2012, 109(14):5299-5304.
26. Patgiri A., Yadav K.K., Arora P.S., Bar-Sagi D. An orthosteric inhibitor of the Ras-Sos interaction. Nat Chem Biol 2011, 7(9):585-587.
27. Zorde Khvalevsky E., Gabai R., Rachmut I.H., et al. Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci USA 2013, 110(51):20723-20728.
28. Sun Q., Burke J.P., Phan J., et al. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angewandte Chemie 2012, 51(25):6140-6143.
29. Ostrem J.M., Peters U., Sos M.L., Wells J.A., Shokat K.M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013, 503(7477):548-551.
30. Golan T., Khvalevsky E.Z., Hubert A., et al. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget 2015.
31. Cox A.D., Der C.J., Philips M.R. Targeting RAS membrane association: back to the future for Anti-RAS drug discovery?. Clin Cancer Res Off J Am Assoc Cancer Res 2015, 21(8):1819-1827.
32. Eser S., Reiff N., Messer M., et al. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 2013, 23(3):406-420.
33. Feldman M.E., Shokat K.M. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of tor kinase domain inhibitors (TORKinibs). Curr Top Microbiol Immunol 2010, 347:241-262.
34. Lim K.H., Counter C.M. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell 2005, 8(5):381-392.
35. Ardito C.M., Gruner B.M., Takeuchi K.K., et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 2012, 22(3):304-317.
36. Walters D.M., Lindberg J.M., Adair S.J., et al. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib. Neoplasia 2013, 15(2):143-155.
37. Hofmann I., Weiss A., Elain G., et al. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PloS One 2012, 7(8):e44146.
38. Infante J.R., Somer B.G., Park J.O., et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer 2014, 50(12):2072-2081.
39. Riess H, Van Laethem J-L, Martens UM, et al., Phase II study of the MEK inhibitor refametinib (BAY 86-9766) in combination with gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer: Biomarker results, ASCO Meeting Abstracts, 32 (suppl. 15), 2014, p. 4129.
40. Jerby-Arnon L., Pfetzer N., Waldman Y.Y., et al. Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality. Cell 2014, 158(5):1199-1209.
41. Corcoran R.B., Cheng K.A., Hata A.N., et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013, 23(1):121-128.
42. Zhu Z., Aref A.R., Cohoon T.J., et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov 2014, 4(4):452-465.
43. Heilmann A.M., Perera R.M., Ecker V., et al. CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers. Cancer Res 2014, 74(14):3947-3958.
44. Liu F., Korc M. Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Therapeutics 2012, 11(10):2138-2148.
45. Franco J., Witkiewicz A.K., Knudsen E.S. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget 2014, 5(15):6512-6525.
46. Witkiewicz A.K., Borja N.A., Franco J., et al. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. Oncotarget 2015.
47. Shao D.D., Xue W., Krall E.B., et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 2014, 158(1):171-184.
48. Kapoor A., Yao W., Ying H., et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 2014, 158(1):185-197.
49. Lin L., Sabnis A.J., Chan E., et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet 2015, 47(3):250-256.
50. Downward J. RAS synthetic lethal screens revisited: still seeking the elusive prize?. Clin Cancer Res Off J Am Assoc Cancer Res 2015, 21(8):1802-1809.
51. Holter S., Borgida A., Dodd A., et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol Off J Am Soc Clin Oncol 2015.
52. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002, 108(2):171-182.
53. Tutt A., Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 2002, 8(12):571-576.
54. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434(7035):917-921.
55. Tutt A.N., Lord C.J., McCabe N., et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harbor Symp Quant Biol 2005, 70:139-148.
56. Cass I., Baldwin R.L., Varkey T., Moslehi R., Narod S.A., Karlan B.Y. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003, 97(9):2187-2195.
57. Golan T., Kanji Z.S., Epelbaum R., et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 2014, 111(6):1132-1138.
58. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434(7035):913-917.
59. van der Heijden M.S., Brody J.R., Dezentje D.A., et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res Off J Am Assoc Cancer Res 2005, 11(20):7508-7515.
60. Brennan G.T., Relias V., Saif M.W. BRCA and pancreatic cancer. JOP J Pancreas 2013, 14(4):325-328.
61. Fogelman D.R., Wolff R.A., Kopetz S., et al. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res 2011, 31(4):1417-1420.
62. Kaufman B., Shapira-Frommer R., Schmutzler R.K., et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol Off J Am Soc Clin Oncol 2015, 33(3):244-250.
63. Fogelman D., Sugar E.A., Oliver G., et al. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2015.
64. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Campbell P.J., Stratton M.R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep 2013, 3(1):246-259.
65. Waddell N., Pajic M., Patch A.M., et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015, 518(7540):495-501.
66. Chmielecki J., Hutchinson K.E., Frampton G.M., et al. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. Cancer Discov 2014, 4(12):1398-1405.
67. Drew Y., Mulligan E.A., Vong W.T., et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 2011, 103(4):334-346.
68. Kim H.S., Kim M.A., Hodgson D., et al. Concordance of ATM (ataxia telangiectasia mutated) immunohistochemistry between biopsy or metastatic tumor samples and primary tumors in gastric cancer patients. Pathobiol J Immunopathol Mol Cell Biol 2013, 80(3):127-137.
69. Kim H., Saka B., Knight S., et al. Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis. Clin Cancer Res Off J Am Assoc Cancer Res 2014, 20(7):1865-1872.
70. Weston V.J., Oldreive C.E., Skowronska A., et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 2010, 116(22):4578-4587.
71. Williamson C.T., Kubota E., Hamill J.D., et al. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. EMBO Mol Med 2012, 4(6):515-527.
72. Williamson C.T., Muzik H., Turhan A.G., et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Therapeutics 2010, 9(2):347-357.
73. Bang Y-J, Im S-A, Lee K-W, et al., Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: a randomized, double-blind phase II study, ASCO Meeting Abstracts, 31 (suppl. 15), 2013, p. 4013.
74. Rizvi N.A., Hellmann M.D., Snyder A., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015, 348(6230):124-128.
75. Carbognin L., Pilotto S., Milella M., et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PloS One 2015, 10(6):e0130142.
76. Millis SZ, Abbott BL, Baker EH, et al., Multiplatform molecular profiling of pancreatic adenocarcinomas to identify BRCA1/2 mutations and PD-1/PD-L1 status with therapeutic implications, ASCO Meeting Abstracts, 33 (Suppl. 15), p. 4124.
77. Higuchi T., Flies D.B., Marjon N.A., et al. CTLA-4 blockade synergizes therapeutically with PARP-inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol Res 2015.
78. Xiao Y., Freeman G.J. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov 2015, 5(1):16-18.
79. Keenan B.P., Saenger Y., Kafrouni M.I., et al. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology 2014, 146(7):1784-1794. e6.
80. Fukunaga A., Miyamoto M., Cho Y., et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 2004, 28(1):e26-31.
81. Hardacre J.M., Mulcahy M., Small W. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg Off J Soc Surg Aliment Tract 2013, 17(1):94-100. discussion p -1.
82. Le D.T., Wang-Gillam A., Picozzi V., et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol Off J Am Soc Clin Oncol 2015, 33(12):1325-1333.
83. Royal R.E., Levy C., Turner K., et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010, 33(8):828-833.
84. Vonderheide R.H., Bajor D.L., Winograd R., Evans R.A., Bayne L.J., Beatty G.L. CD40 immunotherapy for pancreatic cancer. Cancer Immunol Immunother CII 2013, 62(5):949-954.
85. Koblish H.K., Hansbury M.J., Bowman K.J., et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Therapeutics 2010, 9(2):489-498.
86. Wilke C.M., Wei S., Wang L., Kryczek I., Kao J., Zou W. Dual biological effects of the cytokines interleukin-10 and interferon-gamma. Cancer Immunol Immunother CII 2011, 60(11):1529-1541.
87. Mumm J.B., Emmerich J., Zhang X., et al. IL-10 elicits IFNgamma-dependent tumor immune surveillance. Cancer Cell 2011, 20(6):781-796.
88. Leao I.C., Ganesan P., Armstrong T.D., Jaffee E.M. Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma. Clin Trans Sci 2008, 1(3):228-239.
89. Beatty G.L. Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma. Oncoimmunology 2014, 3:e28327.